MA39914A - Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 - Google Patents
Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1Info
- Publication number
- MA39914A MA39914A MA039914A MA39914A MA39914A MA 39914 A MA39914 A MA 39914A MA 039914 A MA039914 A MA 039914A MA 39914 A MA39914 A MA 39914A MA 39914 A MA39914 A MA 39914A
- Authority
- MA
- Morocco
- Prior art keywords
- dopamine
- ligands
- compounds
- heteroaromatic compounds
- schizophrenia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
Abstract
La présente invention concerne, en partie, des composés de formule i : et des sels pharmaceutiquement acceptables correspondants ; des procédés pour leur préparation ; des intermédiaires utilisés dans leur préparation ; et des compositions contenant de tels composés ou sels et leurs utilisations pour le traitement de troubles médiés par la d1 (ou associés à la d1), comprenant par exemple, la schizophrénie (par exemple, ses symptômes cognitifs et négatifs), le trouble de la personnalité schizotypique, une déficience cognitive (par exemple, une déficience cognitive associée à la schizophrénie, à la maladie d'alzheimer, à la maladie de parkinson ou à une pharmacothérapie), le tdah, la maladie de parkinson, l'anxiété et la dépression.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984079P | 2014-04-25 | 2014-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39914A true MA39914A (fr) | 2017-03-01 |
Family
ID=53276921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039914A MA39914A (fr) | 2014-04-25 | 2015-04-09 | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 |
Country Status (26)
Country | Link |
---|---|
US (2) | US9540352B2 (fr) |
EP (1) | EP3134404A1 (fr) |
JP (1) | JP6239149B2 (fr) |
KR (1) | KR20160142402A (fr) |
CN (1) | CN107074843A (fr) |
AP (1) | AP2016009512A0 (fr) |
AU (1) | AU2015249497A1 (fr) |
BR (1) | BR112016023740A2 (fr) |
CA (1) | CA2946475A1 (fr) |
CL (1) | CL2016002677A1 (fr) |
CR (1) | CR20160494A (fr) |
CU (1) | CU20160156A7 (fr) |
DO (1) | DOP2016000289A (fr) |
EA (1) | EA201691788A1 (fr) |
IL (1) | IL248132A0 (fr) |
MA (1) | MA39914A (fr) |
MD (1) | MD20160109A2 (fr) |
MX (1) | MX2016013969A (fr) |
NI (1) | NI201600161A (fr) |
PE (1) | PE20170009A1 (fr) |
PH (1) | PH12016501993A1 (fr) |
SG (1) | SG11201608468TA (fr) |
SV (1) | SV2016005305A (fr) |
TN (1) | TN2016000447A1 (fr) |
TW (1) | TWI561517B (fr) |
WO (1) | WO2015162516A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2946471C (fr) * | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Composes heteroaromatiques bicyclique fusionnes et leur utilisation comme ligands de dopamine d1 |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2015166366A1 (fr) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Composés hétérocycliques et leur utilisation comme ligands des récepteurs d1 de la dopamine |
PT3562821T (pt) | 2016-12-28 | 2021-03-03 | Minoryx Therapeutics S L | Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63145272A (ja) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | 4,5−ジヒドロ−6−(4−置換フエニル)−3(2h)−ピリダジノン誘導体 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JP2004510712A (ja) | 2000-09-22 | 2004-04-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | オクタヒドロ−インドリジンおよびキノリジンおよびヘキサヒドロ−ピロリジン |
EP1746096A1 (fr) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | Analogues de 2-arylbenzothiazole utiles comme agents anticancereux |
CA2615420A1 (fr) * | 2005-07-15 | 2007-01-25 | 4Sc Ag | 2-arylbenzothiazoles et leurs utilisations |
EP2084127A1 (fr) * | 2006-11-13 | 2009-08-05 | Pfizer Products Inc. | Dérivés diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations |
PE20110834A1 (es) * | 2008-12-06 | 2011-12-14 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) |
US20110288090A1 (en) * | 2009-02-02 | 2011-11-24 | Armstrong Donna J | Inhibitors of AKT Activity |
CA2789427A1 (fr) * | 2010-02-11 | 2011-08-18 | Vanderbilt University | Composes de pyrazolopyridine, de pyrazolopyrazine, de pyrazolopyrimidine, de pyrazolothiophene et de pyrazolothiazole en tant que potentialisateurs allosteriques du sous-type 4 durecepteur du glutamate metabotropique (mglur4), composes et procedes de traitement de dysfonctionnements neurologiques |
CA2789474A1 (fr) * | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibiteurs de catechol o-methyl transferase et utilisation associee dans le traitement de troubles psychotiques |
MX345552B (es) * | 2010-03-24 | 2017-02-02 | Amitech Therapeutic Solutions Inc | Compuestos heterocíclicos útiles para inhibición de cinasa. |
CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
WO2014059185A1 (fr) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation |
ES2649144T3 (es) | 2012-11-08 | 2018-01-10 | Pfizer Inc. | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 |
AP3861A (en) | 2012-11-08 | 2016-10-31 | Pfizer | Heteroaromatic compounds as dopamine d1 ligands |
CN102964340B (zh) * | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
PL3013813T3 (pl) * | 2013-06-27 | 2019-10-31 | Pfizer | Związki heteroaromatyczne i ich zastosowanie jako ligandy dopaminy d1 |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
CA2946471C (fr) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Composes heteroaromatiques bicyclique fusionnes et leur utilisation comme ligands de dopamine d1 |
WO2015166366A1 (fr) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Composés hétérocycliques et leur utilisation comme ligands des récepteurs d1 de la dopamine |
US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
-
2015
- 2015-04-09 KR KR1020167032884A patent/KR20160142402A/ko not_active Application Discontinuation
- 2015-04-09 AP AP2016009512A patent/AP2016009512A0/en unknown
- 2015-04-09 MA MA039914A patent/MA39914A/fr unknown
- 2015-04-09 CA CA2946475A patent/CA2946475A1/fr not_active Abandoned
- 2015-04-09 AU AU2015249497A patent/AU2015249497A1/en not_active Abandoned
- 2015-04-09 EA EA201691788A patent/EA201691788A1/ru unknown
- 2015-04-09 MX MX2016013969A patent/MX2016013969A/es unknown
- 2015-04-09 MD MDA20160109A patent/MD20160109A2/ro not_active Application Discontinuation
- 2015-04-09 PE PE2016002126A patent/PE20170009A1/es not_active Application Discontinuation
- 2015-04-09 JP JP2016564000A patent/JP6239149B2/ja not_active Expired - Fee Related
- 2015-04-09 TN TN2016000447A patent/TN2016000447A1/en unknown
- 2015-04-09 CR CR20160494A patent/CR20160494A/es unknown
- 2015-04-09 WO PCT/IB2015/052604 patent/WO2015162516A1/fr active Application Filing
- 2015-04-09 EP EP15726685.9A patent/EP3134404A1/fr not_active Withdrawn
- 2015-04-09 CN CN201580021950.5A patent/CN107074843A/zh active Pending
- 2015-04-09 SG SG11201608468TA patent/SG11201608468TA/en unknown
- 2015-04-09 BR BR112016023740A patent/BR112016023740A2/pt not_active IP Right Cessation
- 2015-04-22 TW TW104112874A patent/TWI561517B/zh not_active IP Right Cessation
- 2015-04-23 US US14/694,333 patent/US9540352B2/en active Active
-
2016
- 2016-03-22 US US15/077,229 patent/US9850232B2/en active Active
- 2016-09-29 IL IL248132A patent/IL248132A0/en unknown
- 2016-10-07 PH PH12016501993A patent/PH12016501993A1/en unknown
- 2016-10-20 CL CL2016002677A patent/CL2016002677A1/es unknown
- 2016-10-21 NI NI201600161A patent/NI201600161A/es unknown
- 2016-10-24 CU CUP2016000156A patent/CU20160156A7/es unknown
- 2016-10-25 SV SV2016005305A patent/SV2016005305A/es unknown
- 2016-10-25 DO DO2016000289A patent/DOP2016000289A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SV2016005305A (es) | 2017-07-19 |
EP3134404A1 (fr) | 2017-03-01 |
JP2017513881A (ja) | 2017-06-01 |
SG11201608468TA (en) | 2016-11-29 |
TWI561517B (en) | 2016-12-11 |
AP2016009512A0 (en) | 2016-10-31 |
WO2015162516A1 (fr) | 2015-10-29 |
NI201600161A (es) | 2016-11-25 |
US20160200711A1 (en) | 2016-07-14 |
TN2016000447A1 (en) | 2018-04-04 |
US9850232B2 (en) | 2017-12-26 |
PE20170009A1 (es) | 2017-03-17 |
CN107074843A (zh) | 2017-08-18 |
MD20160109A2 (ro) | 2017-04-30 |
US20150307494A1 (en) | 2015-10-29 |
TW201604188A (zh) | 2016-02-01 |
MX2016013969A (es) | 2017-01-11 |
PH12016501993A1 (en) | 2017-01-09 |
JP6239149B2 (ja) | 2017-11-29 |
CL2016002677A1 (es) | 2017-02-10 |
AU2015249497A1 (en) | 2016-10-20 |
CR20160494A (es) | 2016-12-20 |
US9540352B2 (en) | 2017-01-10 |
EA201691788A1 (ru) | 2017-03-31 |
CU20160156A7 (es) | 2017-02-02 |
BR112016023740A2 (pt) | 2017-08-15 |
CA2946475A1 (fr) | 2015-10-29 |
DOP2016000289A (es) | 2017-02-15 |
IL248132A0 (en) | 2016-11-30 |
KR20160142402A (ko) | 2016-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. | |
IN2014DN09826A (fr) | ||
CL2008003138A1 (es) | Compuestos derivados de 6-(alcoxi o fenilalcoxi)-indan-1-alquil aminas aciladas; composicion farmaceutica; y uso para el tratamiento o prevencion de alteraciones melatoninergicos tales como depresion, alteraciones del sueno, diabetes, parkinson y enfermedad de alzheimer. | |
EA201491291A1 (ru) | АГОНИСТЫ mGlu 2/3 | |
IN2013MU03838A (fr) |